You are here

AbbVie

AbbVie, Alvotech settle Humira patent and trade secrets disputes, teeing up another biosim rollout next year

Fierce Pharma

Wed, 03/9/22 - 10:46 am

AbbVie closes U.S. pension plan to new hires

Pensions and Investments

Thu, 03/3/22 - 10:36 am

employee benefits

Rare disease and neurology take outs tick higher

EP Vantage

Wed, 03/2/22 - 10:03 am

Bristol Myers Squibb

Gilead Sciences

Jazz Pharmaceuticals

AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect

Fierce Biotech

Tue, 03/1/22 - 10:42 am

Syndesi Therapeutics

Alzheimer's disease

AbbVie files sNDA to FDA for chronic graft versus host disease therapy

Pharmaceutical Business Review

Tue, 03/1/22 - 10:24 am

graft vs host disease

AbbVie ditches fibrosis program it paid Morphic $20M for in 2020

Fierce Biotech

Fri, 02/25/22 - 09:56 am

Morphic Therapeutic

idiopathic pulmonary fibrosis

Teva, Endo and more back on the hook in San Francisco opioid trial

Fierce Pharma

Thu, 02/24/22 - 11:00 pm

Teva Pharmaceutical

Endo International

AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

Endpoints

Wed, 02/23/22 - 10:24 pm

major depressive disorder

AbbVie submits sNDA to FDA for major depressive disorder therapy

Pharmaceutical Business Review

Wed, 02/23/22 - 10:18 am

major depressive disorder

AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster?

Motley Fool

Fri, 02/18/22 - 10:30 am

psoriatic arthritis

Organon CEO pins high hopes on upcoming Humira biosimilar launch

Fierce Pharma

Thu, 02/17/22 - 11:18 pm

AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’

Fierce Pharma

Fri, 02/11/22 - 11:46 am

pharma marketing

AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec

Fierce Pharma

Thu, 02/10/22 - 08:02 pm

AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat

Fierce Pharma

Wed, 02/2/22 - 11:50 pm

AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis

Endpoints

Wed, 02/2/22 - 11:46 pm

AbbVie notches reprieve in antitrust case involving blood pressure med snagged in $63B Allergan megamerger

Fierce Pharma

Wed, 01/26/22 - 11:00 am

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis

Yahoo/Zacks.com

Mon, 01/24/22 - 11:30 pm

psoriatic arthritis

What This FDA News Could Mean for AbbVie's Stock

Motley Fool

Mon, 01/24/22 - 10:10 am

3 Clinical Trials to Watch in the First Half of 2022

Motley Fool

Sat, 01/22/22 - 02:20 pm

clinical trials

Arena Pharmaceuticals

Alzheimer's disease

cystic fibrosis

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B

Fierce Pharma

Thu, 01/13/22 - 11:00 am

Pages